Danish cancer specialist Genmab (OMX: GEN) has been awarded marketing authorization in the European Union for a combination therapy of Darzalex (daratumumab) plus bortezomib, thalidomide and dexamethasone (VTd).
The indication covers treatment of adults with multiple myeloma who are eligible for autologous stem cell transplant (ASCT), in the first-line setting.
The decision was widely anticipated, after the advisory panel of the European Medicines Agency gave a positive decision in December 2019.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze